Evidence map›Paper›PMID 41735738›Full record

ArticleRadiologie (Heidelberg, Germany)2026

[Particle radiotherapy for sarcomas : Advantages, challenges and future perspectives].

Katharina Isabel Kozyra

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Katharina Isabel KozyraRadioonkologie & Strahlentherapie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland. katharina.kozyra@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Particle radiotherapy (RT) offers promising treatment options for sarcomas due to its physical and radiobiological advantages. It enables high doses to be delivered to the tumor while minimizing the impact on surrounding tissue. Additionally, the higher biological effectiveness of carbon ions (C12) helps to overcome the radioresistance of many sarcomas. Although prospective comparative studies are lacking, existing data support the clinical use of particle RT. Future technical and biological optimization of particle RT could further improve the oncological outcome.

Indexed as

Heavy Ion RadiotherapySarcomaHumansProton TherapyRadiotherapy DosageBone sarcomaBragg peakLinear energy transferParticle radiotherapySoft tissue sarcoma

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.